How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

First patients dosed in LAUNCH ALS, an investigator-initiated trial in China conducted in partnership with Tenacia Biopharmaceutical, to support accelerated global clinical development strategy ...

SOUTH SAN FRANCISCO, Calif., June 22, 2026--(BUSINESS WIRE)--Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

A FOX News original, Gallagher joined FNC at the network’s launch in 1996 and has covered breaking news stories throughout the past 26 years. On Inauguration Day 2025, he contributed to the extensive ...

Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://doi.org/10.2307/j.ctvjnrt76.5 https ...

On Friday, Claude Code creator Boris Cherny made an appearance at Meta’s @Scale conference and, surprisingly, the first question from the audience was about loops. “Are loops the next hype cycle,” the ...

Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases, today announced the initiation of its global clinical ...